



Cyprotex is a world renowned preclinical discovery/development contract research organisation with a core focus
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.
Cloe® Screen: A high quality screening service which includes solubility, PAMPA, MDR1-MDCK permeability, Caco-2 permeability, cytochrome P450 inhibition, metabolic stability and hERG automated patch clamp.
Cloe® Select: A bespoke experimental service focusing on later stage ADME and DMPK. It includes cytochrome P450 induction, metabolite profiling and identification and P-gp inhibition.
Cloe® Predict: Expertise in predictive modelling using PBPK and QSAR techniques. Our proprietary software Cloe® PK predicts in vivo pharmacokinetics from in vitro ADME and physicochemical data.
| May 7, 2009 Launch of Cloe Gateway Web Portal | ![]() |
| April 30, 2009 Cyprotex launches Cloe® Select UGT1A1 inhibition assay | ![]() |
| April 2, 2009 Cyprotex Launches its New Website | ![]() |
Request a quotation or
one of our publications.




